# Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation

> **NCT00297830** · PHASE2,PHASE3 · COMPLETED · sponsor: **Columbia University** · enrollment: 111 (actual)

## Conditions studied

- Heart Transplantation
- Liver Transplantation
- Bone Resorption

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Alendronate
- **OTHER:** Placebo Zoledronic Acid
- **OTHER:** Placebo Alendronate

## Key facts

- **NCT ID:** NCT00297830
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2010-04
- **Final completion:** 2014-01
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2018-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297830, "Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00297830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*